

Division: Pharmacy Policy	Subject: Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	May 21, 2012, November 23, 2015, October 21, 2019

**XGEVA® (denosumab)**

**LENGTH OF AUTHORIZATION:** Up to six months

**REVIEW CRITERIA:**

- Patient must be  $\geq 18$  years old, **or adolescent with skeletal maturity in unresectable giant cell tumor of the bone.**
- CONFIRMATION OF ONE OF THE FOLLOWING DIAGNOSES:
  - **Multiple Myeloma**
  - Bone metastases from solid tumors confirmed by progress notes or medical records.
  - Giant Cell Tumor of the bone that is unresectable or resection will likely cause severe morbidity.
  - Hypercalcemia of malignancy refractory to bisphosphonate therapy.

**DOSING & ADMINISTRATION:**

**Multiple Myeloma or Bone Metastasis from solid tumors:** 120 mg subcutaneously every 4 weeks.

**Bone or Hypercalcemia of Malignancy:** 120 mg subcutaneously every week for 3 weeks then starting week 5, 120mg subcutaneously every 4 weeks.

**Giant Cell Tumor for adolescents with skeletal maturity and adults:** 120 mg subcutaneously every week for 3 weeks then starting week 5, 120mg subcutaneously every 4 weeks.